Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.62 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.62 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | RAB9A | P51151 | 5/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9166162 | 0.89 | TDP1 (0.72) | KMT2ATDP1SLC6A2SLC6A3LMNA | |
| SCHEMBL9696689 | 0.89 | TDP1 (0.72) | KMT2ATDP1SLC6A2SLC6A3LMNA | |
| SCHEMBL5094893 | 0.88 | KMT2A (0.62) | KMT2ATDP1SLC6A2SLC6A3LMNA | |
| SCHEMBL20078314 | 0.85 | KMT2A (0.58) | KMT2ATDP1SLC6A2SLC6A3LMNA | |
| SCHEMBL26007966 | 0.85 | KMT2A (0.58) | KMT2ATDP1SLC6A2SLC6A3LMNA | |
| SCHEMBL5094821 | 0.85 | KMT2A (0.58) | KMT2ATDP1SLC6A2SLC6A3LMNA | |
| SCHEMBL26736622 | 0.85 | KMT2A (0.58) | KMT2ATDP1SLC6A2SLC6A3LMNA | |
| SCHEMBL5101575 | 0.85 | KMT2A (0.58) | KMT2ATDP1SLC6A2SLC6A3LMNA | |
| SCHEMBL21924208 | 0.84 | KMT2A (0.66) | KMT2ATDP1SLC6A2SLC6A3LMNA | |
| SCHEMBL20472063 | 0.84 | KMT2A (0.59) | KMT2ATDP1SLC6A2SLC6A3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12458706-B2 | Compounds and therapeutic uses thereof | AVVINITY THERAPEUTICS LIMITED (GB) | 2025-11-04 | — | — | US | disclosed |
| CN-113382771-B | Compounds and therapeutic uses thereof | 阿维尼蒂治疗有限公司 | 2025-01-24 | — | — | CN | disclosed |
| CN-110753558-B | Novel compounds and therapeutic uses thereof | 森陶里治疗有限公司 | 2023-10-24 | — | — | CN | disclosed |
| US-11766483-B2 | Compounds and therapeutics uses thereof | Centauri Therapeutics Limited (GB/GB) (GB) | 2023-09-26 | — | — | US | disclosed |
| US-11766483-B2 | Compounds and therapeutics uses thereof | Centauri Therapeutics Limited (GB/GB) (GB) | 2023-09-26 | — | — | US | disclosed |
| US-11766483-B2 | Compounds and therapeutics uses thereof | Centauri Therapeutics Limited (GB/GB) (GB) | 2023-09-26 | — | — | US | disclosed |
| EP-3606561-B1 | NOVEL COMPOUNDS AND THERAPEUTIC USES THEREOF | CENTAURI THERAPEUTICS LTD (GB) | 2023-08-02 | — | — | EP | disclosed |
| EP-3606561-B1 | NOVEL COMPOUNDS AND THERAPEUTIC USES THEREOF | CENTAURI THERAPEUTICS LTD (GB) | 2023-08-02 | — | — | EP | disclosed |
| CN-108472381-B | Compounds and therapeutic uses thereof | 森陶里治疗有限公司 | 2023-06-06 | — | — | CN | disclosed |
| US-20220162262-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USES THEREOF | Centauri Therapeutics Limited (GB/GB) (GB) | 2022-05-26 | — | — | US | disclosed |
| EP-2718280-B1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMA SPA (IT) | 2015-09-16 | — | — | EP | disclosed |
| EP-2718280-B1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMA SPA (IT) | 2015-09-16 | — | — | EP | disclosed |
| US-8877774-B2 | Compounds having muscarinic receptor antagonist and beta2 Adrenergic receptor agonist activity | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-11-04 | — | — | US | disclosed |
| US-8877774-B2 | Compounds having muscarinic receptor antagonist and beta2 Adrenergic receptor agonist activity | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-11-04 | — | — | US | disclosed |
| US-8877774-B2 | Compounds having muscarinic receptor antagonist and beta2 Adrenergic receptor agonist activity | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-11-04 | — | — | US | disclosed |
| EP-2718280-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | Chiesi Farmaceutici S.p.A. (IT) | 2014-04-16 | — | — | EP | disclosed |
| US-20130045169-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-02-21 | — | — | US | disclosed |
| US-20130045169-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-02-21 | — | — | US | disclosed |
| WO-2012168359-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2012-12-13 | — | — | WO | disclosed |
| WO-2012168359-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2012-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12458706-B2 | Compounds and therapeutic uses thereof | MAVS, NFATC1, MYD88 | KMT2A 3895/4885TDP1 2967/4885SLC6A2 4811/4885 |
| US-20130045169-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | ADRB2, ADRB1, ADRA2B | KMT2A 3123/4885TDP1 4410/4885SLC6A2 1397/4885 |
| US-11766483-B2 | Compounds and therapeutics uses thereof | MAVS, MYD88, CD47 | KMT2A 3577/4885TDP1 2480/4885SLC6A2 4830/4885 |
| US-20220162262-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USES THEREOF | MAVS, MYD88, CD47 | KMT2A 4285/4885TDP1 2941/4885SLC6A2 4757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.